Reviewed By
Overview
SCIENTIFIC SCORE
Possibly Effective
Based on 29 Researches
7
USERS' SCORE
Good
Based on 9 Reviews
8.2
Supplement Facts
Serving Size: 1 Softgel
Amount Per Serving
%DV
Calories
10
Total Fat
1 g
1%*
Polyunsaturated Fat
1 g
†
Fish Oil Concentrate
1 g (1,000 mg)
†
Docosahexaenoic Acid (DHA)
500 mg
†
Eicosapentaenoic Acid (EPA)
250 mg
†
Top Medical Research Studies
9
We investigated the potential benefits of docosahexaenoic acid (DHA) in fighting Alzheimer's disease (AD) through a novel intranasal administration method. By using a specially formulated nanoemulsion that protects DHA from oxidation, we aimed to enhance its delivery to the brain. In our study, we administered this DHA-rich nanoemulsion to J20 mice, a well-known transgenic model for AD.
The results were promising. After treatment, the mice showed notable improvements in their well-being and memory performance, which we measured through their ability to navigate spatial tasks. Additionally, we observed a significant reduction in harmful amyloid deposits, oxidative stress, and neuroinflammation within their brain tissues. This positive outcome could potentially stem from DHA's ability to affect specific processes in the brain, such as the inactivation of GSK3β, a kinase associated with AD.
Overall, our findings suggest that intranasal DHA treatment not only has therapeutic effects but may also modify the progression of Alzheimer's disease. Considering that DHA has already demonstrated safety in humans, we believe there is a strong case for conducting clinical trials to explore this approach further for Alzheimer's patients.
The results were promising. After treatment, the mice showed notable improvements in their well-being and memory performance, which we measured through their ability to navigate spatial tasks. Additionally, we observed a significant reduction in harmful amyloid deposits, oxidative stress, and neuroinflammation within their brain tissues. This positive outcome could potentially stem from DHA's ability to affect specific processes in the brain, such as the inactivation of GSK3β, a kinase associated with AD.
Overall, our findings suggest that intranasal DHA treatment not only has therapeutic effects but may also modify the progression of Alzheimer's disease. Considering that DHA has already demonstrated safety in humans, we believe there is a strong case for conducting clinical trials to explore this approach further for Alzheimer's patients.
Read More
8
We explored the potential of eicosapentaenoic acid (EPA), a type of omega-3 fatty acid, in destabilizing the toxic aggregates of the Aβ protein that form plaques in Alzheimer's disease. The study utilized advanced molecular dynamics simulations to assess how EPA interacts with these fibrils over time.
Throughout the analysis, we observed that EPA not only binds to the Aβ fibrils but also disrupts their structure. As a result, we noted increased root mean square deviation, radius of gyration, and surface area while the number of hydrogen bonds and β-sheet content decreased. This indicates that EPA interferes with the fibrils' stability, potentially paving the way for therapeutic applications in Alzheimer’s treatment.
Importantly, the interactions demonstrated that the polar head of EPA aligns with positively charged residues in the fibril, showcasing a clear mechanism behind its destabilizing effects. The hydrophobic tail of EPA competes with the natural hydrophobic interactions within the fibrils, ultimately leading to their destabilization. Overall, our findings suggest that EPA could be a promising candidate for further drug development aimed at combating Alzheimer’s disease.
Throughout the analysis, we observed that EPA not only binds to the Aβ fibrils but also disrupts their structure. As a result, we noted increased root mean square deviation, radius of gyration, and surface area while the number of hydrogen bonds and β-sheet content decreased. This indicates that EPA interferes with the fibrils' stability, potentially paving the way for therapeutic applications in Alzheimer’s treatment.
Importantly, the interactions demonstrated that the polar head of EPA aligns with positively charged residues in the fibril, showcasing a clear mechanism behind its destabilizing effects. The hydrophobic tail of EPA competes with the natural hydrophobic interactions within the fibrils, ultimately leading to their destabilization. Overall, our findings suggest that EPA could be a promising candidate for further drug development aimed at combating Alzheimer’s disease.
Read More
9
DHA may improve Alzheimer's-related dysfunctions
We set out to explore the influence of docosahexaenoic acid, or DHA, on problems associated with Alzheimer's disease (AD). By using human neuroblastoma cells that express a form of the amyloid precursor protein commonly linked to AD, we observed significant endolysosomal abnormalities. These included enlarged endosomes, a decrease in exosome secretion, and an increase in cell death, supporting the relevance of our model for studying Alzheimer’s mechanisms.
Our findings revealed that DHA treatment seemed to offer neuroprotection. Specifically, we found that DHA helped reduce the interaction between the C99 fragment of the amyloid precursor protein and a protein called Rab5, which plays a crucial role in endosomal function. We also noted effects like smaller endosome sizes, improved exosome production, and decreased apoptosis in the cells treated with DHA.
Overall, our study suggests that DHA may have the potential to correct the dysfunctional interactions and processes within neurons that are characteristic of Alzheimer's disease. This highlights an exciting avenue for further research into nutritional interventions for AD.
Our findings revealed that DHA treatment seemed to offer neuroprotection. Specifically, we found that DHA helped reduce the interaction between the C99 fragment of the amyloid precursor protein and a protein called Rab5, which plays a crucial role in endosomal function. We also noted effects like smaller endosome sizes, improved exosome production, and decreased apoptosis in the cells treated with DHA.
Overall, our study suggests that DHA may have the potential to correct the dysfunctional interactions and processes within neurons that are characteristic of Alzheimer's disease. This highlights an exciting avenue for further research into nutritional interventions for AD.
Read More
Most Useful Reviews
9
Supports brain health
1 people found this helpful
Excellent! DHA is vital for brain health, particularly for those with a family history of Alzheimer's. I appreciate this NOW product as it contains 500mg of DHA per capsule.
Read More
9
Promotes brain function
1 people found this helpful
In the elderly, DHA levels are often low, risking memory loss. Supplementing with DHA is wise for brain and eye development, decreasing the chances of Alzheimer's, dementia, and related issues. It also lowers inflammation and aids in chronic disease management.
Read More
9
Essential nutrition
Very good, very good! This is essential nutrition for preventing Alzheimer's disease.
Read More
Medical Researches
SCIENTIFIC SCORE
Possibly Effective
Based on 29 Researches
7
- All Researches
9
We aimed to uncover how docosahexaenoic acid (DHA) might affect Alzheimer's disease, particularly in relation to nonalcoholic fatty liver disease (NAFLD). Our study involved 40 three-month-old male APP/PS1 mice, which are commonly used in Alzheimer's research, divided into four groups. These groups ate different diets—one with DHA, one with medium-chain triglycerides (MCTs), one with both, and one control—as we observed their impacts on liver health and amyloid-β (Aβ) accumulations over eight months.
Our findings showed that mice with Alzheimer's displayed both NAFLD and increased levels of Aβ in their brains. Interestingly, the combination of DHA and MCTs led to lower blood and liver lipids. It also alleviated fat buildup in the liver and reduced Aβ levels in both the brain and serum. Moreover, it effectively raised the levels of proteins linked to Aβ clearance while altering the expression of key enzymes related to liver lipid metabolism.
In essence, our research suggests that DHA, particularly when paired with MCTs, may offer protective benefits against the progression of NAFLD and simultaneously reduce Aβ accumulation. This could indicate a more significant response to metabolic changes in APP/PS1 mice compared to normal mice. Our study adds to the understanding of DHA's potential role in managing Alzheimer's disease through its effects on liver metabolism and Aβ processing.
Our findings showed that mice with Alzheimer's displayed both NAFLD and increased levels of Aβ in their brains. Interestingly, the combination of DHA and MCTs led to lower blood and liver lipids. It also alleviated fat buildup in the liver and reduced Aβ levels in both the brain and serum. Moreover, it effectively raised the levels of proteins linked to Aβ clearance while altering the expression of key enzymes related to liver lipid metabolism.
In essence, our research suggests that DHA, particularly when paired with MCTs, may offer protective benefits against the progression of NAFLD and simultaneously reduce Aβ accumulation. This could indicate a more significant response to metabolic changes in APP/PS1 mice compared to normal mice. Our study adds to the understanding of DHA's potential role in managing Alzheimer's disease through its effects on liver metabolism and Aβ processing.
Read More
9
We investigated the potential benefits of docosahexaenoic acid (DHA) in fighting Alzheimer's disease (AD) through a novel intranasal administration method. By using a specially formulated nanoemulsion that protects DHA from oxidation, we aimed to enhance its delivery to the brain. In our study, we administered this DHA-rich nanoemulsion to J20 mice, a well-known transgenic model for AD.
The results were promising. After treatment, the mice showed notable improvements in their well-being and memory performance, which we measured through their ability to navigate spatial tasks. Additionally, we observed a significant reduction in harmful amyloid deposits, oxidative stress, and neuroinflammation within their brain tissues. This positive outcome could potentially stem from DHA's ability to affect specific processes in the brain, such as the inactivation of GSK3β, a kinase associated with AD.
Overall, our findings suggest that intranasal DHA treatment not only has therapeutic effects but may also modify the progression of Alzheimer's disease. Considering that DHA has already demonstrated safety in humans, we believe there is a strong case for conducting clinical trials to explore this approach further for Alzheimer's patients.
The results were promising. After treatment, the mice showed notable improvements in their well-being and memory performance, which we measured through their ability to navigate spatial tasks. Additionally, we observed a significant reduction in harmful amyloid deposits, oxidative stress, and neuroinflammation within their brain tissues. This positive outcome could potentially stem from DHA's ability to affect specific processes in the brain, such as the inactivation of GSK3β, a kinase associated with AD.
Overall, our findings suggest that intranasal DHA treatment not only has therapeutic effects but may also modify the progression of Alzheimer's disease. Considering that DHA has already demonstrated safety in humans, we believe there is a strong case for conducting clinical trials to explore this approach further for Alzheimer's patients.
Read More
9
DHA shows potential in AD treatment
We examined how docosahexaenoic acid (DHA), a type of omega-3 fatty acid, could influence Alzheimer's disease (AD) progression. To do this, we crossed special mice known for their ability to produce higher levels of omega-3s with another group genetically predisposed to develop AD. The goal was to see if increased DHA in their brains would improve their cognition and reduce harmful protein levels associated with AD.
Our findings were compelling. Mice with elevated DHA levels showed fewer cognitive deficits and lower levels of amyloid-beta, the protein linked to AD, compared to those that lacked this enhancement. We also found that this improvement was associated with higher expression of myelin-associated glycoprotein (MAG) in key brain areas involved in learning and memory. This suggests a potential mechanism through which DHA exerts its protective effects.
Additionally, our analysis indicated that the protective properties of DHA were compromised when MAG expression was inhibited. This reinforces the idea that up-regulation of MAG is crucial for DHA’s beneficial effects against AD. Overall, our research highlights DHA as a promising avenue for Alzheimer's treatment due to its ability to enhance MAG expression and support cognitive function.
Our findings were compelling. Mice with elevated DHA levels showed fewer cognitive deficits and lower levels of amyloid-beta, the protein linked to AD, compared to those that lacked this enhancement. We also found that this improvement was associated with higher expression of myelin-associated glycoprotein (MAG) in key brain areas involved in learning and memory. This suggests a potential mechanism through which DHA exerts its protective effects.
Additionally, our analysis indicated that the protective properties of DHA were compromised when MAG expression was inhibited. This reinforces the idea that up-regulation of MAG is crucial for DHA’s beneficial effects against AD. Overall, our research highlights DHA as a promising avenue for Alzheimer's treatment due to its ability to enhance MAG expression and support cognitive function.
Read More
9
Cognitive enhancement in Alzheimer’s models
We delved into how docosahexaenoic acid (DHA), when combined with medium-chain triglycerides (MCTs), influences cognitive function, particularly in the context of Alzheimer's disease. In our study, we used two mouse models known for neurodegenerative research, which helped us assess the impact of DHA and MCTs on not just cognitive abilities, but also inflammation and gut microbiota.
The findings revealed that the combination of MCTs and DHA significantly improved spatial learning, memory, and exploratory behavior in these mice. Notably, we observed a reduction in specific inflammation markers and a positive shift in gut microbiota composition, with a decrease in harmful bacteria levels.
Moreover, this dual supplementation outperformed either MCTs or DHA alone, showcasing a unique synergy that could offer new insights into potential dietary interventions aimed at improving cognitive health in Alzheimer's. Overall, our study indicates that the combined effects of MCTs and DHA are promising and could be key in finding new avenues for cognitive enhancement in neurodegenerative conditions.
The findings revealed that the combination of MCTs and DHA significantly improved spatial learning, memory, and exploratory behavior in these mice. Notably, we observed a reduction in specific inflammation markers and a positive shift in gut microbiota composition, with a decrease in harmful bacteria levels.
Moreover, this dual supplementation outperformed either MCTs or DHA alone, showcasing a unique synergy that could offer new insights into potential dietary interventions aimed at improving cognitive health in Alzheimer's. Overall, our study indicates that the combined effects of MCTs and DHA are promising and could be key in finding new avenues for cognitive enhancement in neurodegenerative conditions.
Read More
9
DHA may improve Alzheimer's-related dysfunctions
We set out to explore the influence of docosahexaenoic acid, or DHA, on problems associated with Alzheimer's disease (AD). By using human neuroblastoma cells that express a form of the amyloid precursor protein commonly linked to AD, we observed significant endolysosomal abnormalities. These included enlarged endosomes, a decrease in exosome secretion, and an increase in cell death, supporting the relevance of our model for studying Alzheimer’s mechanisms.
Our findings revealed that DHA treatment seemed to offer neuroprotection. Specifically, we found that DHA helped reduce the interaction between the C99 fragment of the amyloid precursor protein and a protein called Rab5, which plays a crucial role in endosomal function. We also noted effects like smaller endosome sizes, improved exosome production, and decreased apoptosis in the cells treated with DHA.
Overall, our study suggests that DHA may have the potential to correct the dysfunctional interactions and processes within neurons that are characteristic of Alzheimer's disease. This highlights an exciting avenue for further research into nutritional interventions for AD.
Our findings revealed that DHA treatment seemed to offer neuroprotection. Specifically, we found that DHA helped reduce the interaction between the C99 fragment of the amyloid precursor protein and a protein called Rab5, which plays a crucial role in endosomal function. We also noted effects like smaller endosome sizes, improved exosome production, and decreased apoptosis in the cells treated with DHA.
Overall, our study suggests that DHA may have the potential to correct the dysfunctional interactions and processes within neurons that are characteristic of Alzheimer's disease. This highlights an exciting avenue for further research into nutritional interventions for AD.
Read More
User Reviews
USERS' SCORE
Good
Based on 9 Reviews
8.2
- All Reviews
- Positive Reviews
- Negative Reviews
9
Supports brain health
1 people found this helpful
Excellent! DHA is vital for brain health, particularly for those with a family history of Alzheimer's. I appreciate this NOW product as it contains 500mg of DHA per capsule.
Read More
9
Promotes brain function
1 people found this helpful
In the elderly, DHA levels are often low, risking memory loss. Supplementing with DHA is wise for brain and eye development, decreasing the chances of Alzheimer's, dementia, and related issues. It also lowers inflammation and aids in chronic disease management.
Read More
9
Essential nutrition
Very good, very good! This is essential nutrition for preventing Alzheimer's disease.
Read More
7.5
Reduced Alzheimer's risk
31 people found this helpful
Great stuff. Our doctor recommended 1200mg of DHA for my husband daily due to his blood tests indicating a higher probability of developing Alzheimer's disease as he ages. He mentioned this could lessen those probabilities. Additionally, our cholesterol levels have significantly decreased. This product is a fantastic value, with no fishy aftertaste or burping. We plan to continue using it.
Read More
7.5
Protects against alzheimer
1 people found this helpful
DHA is crucial for the central nervous system. A deficiency can diminish mental performance and memory while increasing the risk of conditions like Alzheimer's. It also aids in forming the myelin sheath of nerves, ensuring effective nerve impulse conduction. I highly recommend it!
Read More
Frequently Asked Questions
9
Promotes brain function
1 people found this helpful
In the elderly, DHA levels are often low, risking memory loss. Supplementing with DHA is wise for brain and eye development, decreasing the chances of Alzheimer's, dementia, and related issues. It also lowers inflammation and aids in chronic disease management.
9
Essential nutrition
Very good, very good! This is essential nutrition for preventing Alzheimer's disease.
7.5
Protects against alzheimer
1 people found this helpful
DHA is crucial for the central nervous system. A deficiency can diminish mental performance and memory while increasing the risk of conditions like Alzheimer's. It also aids in forming the myelin sheath of nerves, ensuring effective nerve impulse conduction. I highly recommend it!
9
Supports brain health
1 people found this helpful
Excellent! DHA is vital for brain health, particularly for those with a family history of Alzheimer's. I appreciate this NOW product as it contains 500mg of DHA per capsule.
9
We investigated the potential benefits of docosahexaenoic acid (DHA) in fighting Alzheimer's disease (AD) through a novel intranasal administration method. By using a specially formulated nanoemulsion that protects DHA from oxidation, we aimed to enhance its delivery to the brain. In our study, we administered this DHA-rich nanoemulsion to J20 mice, a well-known transgenic model for AD.
The results were promising. After treatment, the mice showed notable improvements in their well-being and memory performance, which we measured through their ability to navigate spatial tasks. Additionally, we observed a significant reduction in harmful amyloid deposits, oxidative stress, and neuroinflammation within their brain tissues. This positive outcome could potentially stem from DHA's ability to affect specific processes in the brain, such as the inactivation of GSK3β, a kinase associated with AD.
Overall, our findings suggest that intranasal DHA treatment not only has therapeutic effects but may also modify the progression of Alzheimer's disease. Considering that DHA has already demonstrated safety in humans, we believe there is a strong case for conducting clinical trials to explore this approach further for Alzheimer's patients.
The results were promising. After treatment, the mice showed notable improvements in their well-being and memory performance, which we measured through their ability to navigate spatial tasks. Additionally, we observed a significant reduction in harmful amyloid deposits, oxidative stress, and neuroinflammation within their brain tissues. This positive outcome could potentially stem from DHA's ability to affect specific processes in the brain, such as the inactivation of GSK3β, a kinase associated with AD.
Overall, our findings suggest that intranasal DHA treatment not only has therapeutic effects but may also modify the progression of Alzheimer's disease. Considering that DHA has already demonstrated safety in humans, we believe there is a strong case for conducting clinical trials to explore this approach further for Alzheimer's patients.
9
We aimed to uncover how docosahexaenoic acid (DHA) might affect Alzheimer's disease, particularly in relation to nonalcoholic fatty liver disease (NAFLD). Our study involved 40 three-month-old male APP/PS1 mice, which are commonly used in Alzheimer's research, divided into four groups. These groups ate different diets—one with DHA, one with medium-chain triglycerides (MCTs), one with both, and one control—as we observed their impacts on liver health and amyloid-β (Aβ) accumulations over eight months.
Our findings showed that mice with Alzheimer's displayed both NAFLD and increased levels of Aβ in their brains. Interestingly, the combination of DHA and MCTs led to lower blood and liver lipids. It also alleviated fat buildup in the liver and reduced Aβ levels in both the brain and serum. Moreover, it effectively raised the levels of proteins linked to Aβ clearance while altering the expression of key enzymes related to liver lipid metabolism.
In essence, our research suggests that DHA, particularly when paired with MCTs, may offer protective benefits against the progression of NAFLD and simultaneously reduce Aβ accumulation. This could indicate a more significant response to metabolic changes in APP/PS1 mice compared to normal mice. Our study adds to the understanding of DHA's potential role in managing Alzheimer's disease through its effects on liver metabolism and Aβ processing.
Our findings showed that mice with Alzheimer's displayed both NAFLD and increased levels of Aβ in their brains. Interestingly, the combination of DHA and MCTs led to lower blood and liver lipids. It also alleviated fat buildup in the liver and reduced Aβ levels in both the brain and serum. Moreover, it effectively raised the levels of proteins linked to Aβ clearance while altering the expression of key enzymes related to liver lipid metabolism.
In essence, our research suggests that DHA, particularly when paired with MCTs, may offer protective benefits against the progression of NAFLD and simultaneously reduce Aβ accumulation. This could indicate a more significant response to metabolic changes in APP/PS1 mice compared to normal mice. Our study adds to the understanding of DHA's potential role in managing Alzheimer's disease through its effects on liver metabolism and Aβ processing.
7
We explored the effects of docosahexaenoic acid (DHA) on Alzheimer’s disease by using 3xTg-AD mice in a controlled study. Over three months, these mice were divided into different diet groups: one received a control diet with no DHA or EPA, the second was given a diet rich in DHA, and the third had a higher intake of eicosapentaenoic acid (EPA) alongside DHA.
Our findings showed that both the DHA and DHA + EPA diets increased omega-3 levels in the brain and lowered arachidonic acid levels. Importantly, both groups also saw a significant reduction in soluble phosphorylated tau, a key biomarker linked to Alzheimer's disease. Specifically, the mice on the high DHA diet and those on the DHA + EPA diet showed about a 34% decrease in tau levels.
While DHA clearly demonstrated positive effects on tau-related pathology, we found no significant changes in amyloid-beta levels, which is another crucial aspect of Alzheimer's disease. The results indicate that dietary intake of DHA can lead to beneficial changes in brain biomarkers associated with Alzheimer’s, highlighting its potential role in combating this neurodegenerative condition.
Our findings showed that both the DHA and DHA + EPA diets increased omega-3 levels in the brain and lowered arachidonic acid levels. Importantly, both groups also saw a significant reduction in soluble phosphorylated tau, a key biomarker linked to Alzheimer's disease. Specifically, the mice on the high DHA diet and those on the DHA + EPA diet showed about a 34% decrease in tau levels.
While DHA clearly demonstrated positive effects on tau-related pathology, we found no significant changes in amyloid-beta levels, which is another crucial aspect of Alzheimer's disease. The results indicate that dietary intake of DHA can lead to beneficial changes in brain biomarkers associated with Alzheimer’s, highlighting its potential role in combating this neurodegenerative condition.
9
Cognitive enhancement in Alzheimer’s models
We delved into how docosahexaenoic acid (DHA), when combined with medium-chain triglycerides (MCTs), influences cognitive function, particularly in the context of Alzheimer's disease. In our study, we used two mouse models known for neurodegenerative research, which helped us assess the impact of DHA and MCTs on not just cognitive abilities, but also inflammation and gut microbiota.
The findings revealed that the combination of MCTs and DHA significantly improved spatial learning, memory, and exploratory behavior in these mice. Notably, we observed a reduction in specific inflammation markers and a positive shift in gut microbiota composition, with a decrease in harmful bacteria levels.
Moreover, this dual supplementation outperformed either MCTs or DHA alone, showcasing a unique synergy that could offer new insights into potential dietary interventions aimed at improving cognitive health in Alzheimer's. Overall, our study indicates that the combined effects of MCTs and DHA are promising and could be key in finding new avenues for cognitive enhancement in neurodegenerative conditions.
The findings revealed that the combination of MCTs and DHA significantly improved spatial learning, memory, and exploratory behavior in these mice. Notably, we observed a reduction in specific inflammation markers and a positive shift in gut microbiota composition, with a decrease in harmful bacteria levels.
Moreover, this dual supplementation outperformed either MCTs or DHA alone, showcasing a unique synergy that could offer new insights into potential dietary interventions aimed at improving cognitive health in Alzheimer's. Overall, our study indicates that the combined effects of MCTs and DHA are promising and could be key in finding new avenues for cognitive enhancement in neurodegenerative conditions.
5
DHA's role in Alzheimer's examined
We dove into the effects of docosahexaenoic acid (DHA) supplementation on cognitive decline in individuals with mild cognitive impairment and Alzheimer's disease. Our analysis involved eleven randomized controlled trials, where we sought to answer whether DHA could help improve cognitive function and slow brain atrophy among the elderly suffering from these conditions.
The results were mixed; some studies showed promising cognitive benefits from DHA, particularly relating to memory preservation and maintaining hippocampal volume in earlier stages of cognitive decline. However, it seemed that as Alzheimer's progresses, the effects of DHA became less significant, with certain studies reporting little to no impact.
We also noted that variations in study design, including dosage, intervention length, and the characteristics of participants, might explain the differences in outcomes. Despite some uncertainties, DHA’s generally favorable safety profile encourages its consideration in clinical approaches to early intervention for at-risk individuals.
This review pushes us to think about the importance of more extensive, longer-term studies to better understand optimal DHA dosages, timing for intervention, and how genetic factors may tailor its use. Overall, the findings support the ongoing exploration of omega-3 fatty acids as potential allies in addressing cognitive decline.
The results were mixed; some studies showed promising cognitive benefits from DHA, particularly relating to memory preservation and maintaining hippocampal volume in earlier stages of cognitive decline. However, it seemed that as Alzheimer's progresses, the effects of DHA became less significant, with certain studies reporting little to no impact.
We also noted that variations in study design, including dosage, intervention length, and the characteristics of participants, might explain the differences in outcomes. Despite some uncertainties, DHA’s generally favorable safety profile encourages its consideration in clinical approaches to early intervention for at-risk individuals.
This review pushes us to think about the importance of more extensive, longer-term studies to better understand optimal DHA dosages, timing for intervention, and how genetic factors may tailor its use. Overall, the findings support the ongoing exploration of omega-3 fatty acids as potential allies in addressing cognitive decline.
8
We delved into the potential of docosahexaenoic acid (DHA) as a treatment for Alzheimer's Disease (AD) based on findings from recent clinical trials. The evidence so far indicates that DHA may play a role in cognitive improvement for some individuals, though these effects have not consistently translated into significant benefits specifically for Alzheimer's patients.
Our review highlighted that DHA, an omega-3 fatty acid, is naturally found in the human body, and compounds like it tended to show more promising results in studies. Notably, among the 13 natural products we examined, DHA emerged as a key contender with considerable potential as a therapeutic option for AD.
While these findings are encouraging, it’s important to note that natural products, including DHA, may work better as supplements rather than primary treatments for Alzheimer's. Moreover, due to the complexity of AD and the varied pathways that natural products could influence, more extensive research is needed to fully understand the role of DHA in managing this challenging condition.
Our review highlighted that DHA, an omega-3 fatty acid, is naturally found in the human body, and compounds like it tended to show more promising results in studies. Notably, among the 13 natural products we examined, DHA emerged as a key contender with considerable potential as a therapeutic option for AD.
While these findings are encouraging, it’s important to note that natural products, including DHA, may work better as supplements rather than primary treatments for Alzheimer's. Moreover, due to the complexity of AD and the varied pathways that natural products could influence, more extensive research is needed to fully understand the role of DHA in managing this challenging condition.
References
- Zhang D, Wang Z, Wang X, Yue W, Zhang L, et al. Cosupplementation with DHA and medium-chain triglycerides ameliorates NAFLD and reduces amyloid-β accumulation by modulating hepatic lipid metabolism in APP/PS1 mice. Lipids. 2025. 10.1002/lipd.12436
- Otaegui L, Urgin T, Zaiter T, Zussy C, Vitalis M, et al. Nose-to-brain delivery of DHA-loaded nanoemulsions: A promising approach against Alzheimer's disease. Int J Pharm. 2025;670:125125. 10.1016/j.ijpharm.2024.125125
- Deshmukh GV, Niaz H, Bai R, Kim DH, Kim JW, et al. The Role of Omega-3 Fatty Acid Supplementation in Slowing Cognitive Decline Among Elderly Patients With Alzheimer's Disease: A Systematic Review of Randomized Controlled Trials. Cureus. 2024;16:e73390. 10.7759/cureus.73390
- Jang S, Choi B, Lim C, Kim M, Lee JE, et al. Neuronal fatty acid-binding protein enhances autophagy and suppresses amyloid-β pathology in a Drosophila model of Alzheimer's disease. PLoS Genet. 2024;20:e1011475. 10.1371/journal.pgen.1011475
- Oye Mintsa Mi-Mba MF, Lebbadi M, Alata W, Julien C, Emond V, et al. Differential impact of eicosapentaenoic acid and docosahexaenoic acid in an animal model of Alzheimer's disease. J Lipid Res. 2024;65:100682. 10.1016/j.jlr.2024.100682
- Shao Y, Li F, Zou B, Jin Y, Wang X, et al. Up-regulation of myelin-associated glycoprotein is associated with the ameliorating effect of omega-3 polyunsaturated fatty acids on Alzheimer's disease progression in APP-PS1 transgenic mice. Food Funct. 2024;15:11236. 10.1039/d4fo03355h
- Wang Z, Sun Y, Zhang D, Wang Y, Zhou D, et al. Gut microbiota and inflammation analyses reveal the protective effect of medium-chain triglycerides combined with docosahexaenoic acid on cognitive function in APP/PS1 and SAMP8 mice. Nutr Res. 2024;132:27. 10.1016/j.nutres.2024.09.015
- Bai D, Fan J, Li M, Dong C, Gao Y, et al. Cognitive Function After Stopping Folic Acid and DHA Intervention: An Extended Follow-Up Results from the Randomized, Double Blind, Placebo-Controlled Trial in Older Adults with Mild Cognitive Impairment. J Alzheimers Dis Rep. 2024;8:1285. 10.3233/ADR-240033
- Vigier M, Uriot M, Djelti-Delbarba F, Claudepierre T, El Hajj A, et al. Increasing the Survival of a Neuronal Model of Alzheimer's Disease Using Docosahexaenoic Acid, Restoring Endolysosomal Functioning by Modifying the Interactions between the Membrane Proteins C99 and Rab5. Int J Mol Sci. 2024;25. 10.3390/ijms25136816
- Lázaro I, Grau-Rivera O, Suárez-Calvet M, Fauria K, Minguillón C, et al. Omega-3 blood biomarkers relate to brain glucose uptake in individuals at risk of Alzheimer's disease dementia. Alzheimers Dement (Amst). 2024;16:e12596. 10.1002/dad2.12596
- Calderon Martinez E, Zachariah Saji S, Salazar Ore JV, Borges-Sosa OA, Srinivas S, et al. The effects of omega-3, DHA, EPA, Souvenaid® in Alzheimer's disease: A systematic review and meta-analysis. Neuropsychopharmacol Rep. 2024;44:545. 10.1002/npr2.12455
- Mohamed Yusof NIS, Mohd Fauzi F. Nature's Toolbox for Alzheimer's Disease: A Review on the Potential of Natural Products as Alzheimer's Disease Drugs. Neurochem Int. 2024;176:105738. 10.1016/j.neuint.2024.105738
- Dakterzada F, Jové M, Cantero JL, Mota-Martorell N, Pamplona R, et al. The shift in the fatty acid composition of the circulating lipidome in Alzheimer's disease. Alzheimers Dement. 2024;20:3322. 10.1002/alz.13792
- Wang Y, Zhang H, Ding F, Li J, Li L, et al. N-3 polyunsaturated fatty acids attenuate amyloid-beta-induced toxicity in AD transgenic Caenorhabditis elegans via promotion of proteasomal activity and activation of PPAR-gamma. J Nutr Biochem. 2024;127:109603. 10.1016/j.jnutbio.2024.109603
- Takekoshi H, Fujishima M, Miyazawa T, Higuchi O, Fujikawa T, et al. Simultaneous Intake of Chlorella and Ascidian Ethanolamine Plasmalogen Accelerates Activation of BDNF-TrkB-CREB Signaling in Rats. Molecules. 2024;29. 10.3390/molecules29020357
- Bhole RP, Chikhale RV, Rathi KM. Current biomarkers and treatment strategies in Alzheimer disease: An overview and future perspectives. IBRO Neurosci Rep. 2024;16:8. 10.1016/j.ibneur.2023.11.003
- Andriambelo B, Vachon A, Dansereau MA, Laurent B, Plourde M. Providing lysophosphatidylcholine-bound omega-3 fatty acids increased eicosapentaenoic acid, but not docosahexaenoic acid, in the cortex of mice with the apolipoprotein E3 or E4 allele. Prostaglandins Leukot Essent Fatty Acids. 2024;204:102661. 10.1016/j.plefa.2024.102661
- Shinto LH, Murchison CF, Silbert LC, Dodge HH, Lahna D, et al. ω-3 PUFA for Secondary Prevention of White Matter Lesions and Neuronal Integrity Breakdown in Older Adults: A Randomized Clinical Trial. JAMA Netw Open. 2024;7:e2426872. 10.1001/jamanetworkopen.2024.26872
- Wang YW, Li Q, Li XY, Zhao YC, Wang CC, et al. A Comparative Study about the Neuroprotective Effects of DHA-Enriched Phosphatidylserine and EPA-Enriched Phosphatidylserine against Oxidative Damage in Primary Hippocampal Neurons. Mar Drugs. 2023;21. 10.3390/md21070410
- Sugasini D, Park JC, McAnany JJ, Kim TH, Ma G, et al. Improvement of retinal function in Alzheimer disease-associated retinopathy by dietary lysophosphatidylcholine-EPA/DHA. Sci Rep. 2023;13:9179. 10.1038/s41598-023-36268-0
- Tseng PT, Zeng BS, Suen MW, Wu YC, Correll CU, et al. Efficacy and acceptability of anti-inflammatory eicosapentaenoic acid for cognitive function in Alzheimer's dementia: A network meta-analysis of randomized, placebo-controlled trials with omega-3 fatty acids and FDA-approved pharmacotherapy. Brain Behav Immun. 2023;111:352. 10.1016/j.bbi.2023.04.017
- Wei BZ, Li L, Dong CW, Tan CC, Xu W. The Relationship of Omega-3 Fatty Acids with Dementia and Cognitive Decline: Evidence from Prospective Cohort Studies of Supplementation, Dietary Intake, and Blood Markers. Am J Clin Nutr. 2023;117:1096. 10.1016/j.ajcnut.2023.04.001
- Yavari M, Ramalingam L, Harris BN, Kahathuduwa CN, Chavira A, et al. Eicosapentaenoic Acid Protects against Metabolic Impairments in the APPswe/PS1dE9 Alzheimer's Disease Mouse Model. J Nutr. 2023;153:1038. 10.1016/j.tjnut.2023.01.030
- Yang L, Zhao F, Sun Y, Wang Z, Li Q, et al. N-3 Polyunsaturated Fatty Acids in Elderly with Mild Cognitive Impairment: A Systemic Review and Meta-Analysis. J Alzheimers Dis. 2024;99:S81. 10.3233/JAD-220863
- Li Y, Lai W, Zheng C, Babu JR, Xue C, et al. Neuroprotective Effect of Stearidonic Acid on Amyloid β-Induced Neurotoxicity in Rat Hippocampal Cells. Antioxidants (Basel). 2022;11. 10.3390/antiox11122357
- Torres-Mendoza BMG, Ortiz GG, Sánchez-Romero L, Delgado-Lara DLC, García Martínez MT, et al. Dietary fish oil increases catalase activity in patients with probable Alzheimer's disease. Nutr Hosp. 2022;39:1364. 10.20960/nh.04153
- Chu CS, Hung CF, Ponnusamy VK, Chen KC, Chen NC. Higher Serum DHA and Slower Cognitive Decline in Patients with Alzheimer's Disease: Two-Year Follow-Up. Nutrients. 2022;14. 10.3390/nu14061159
- Gupta S, Dasmahapatra AK. Destabilization of Aβ fibrils by omega-3 polyunsaturated fatty acids: a molecular dynamics study. J Biomol Struct Dyn. 2023;41:581. 10.1080/07391102.2021.2009915
- Lin PY, Cheng C, Satyanarayanan SK, Chiu LT, Chien YC, et al. Omega-3 fatty acids and blood-based biomarkers in Alzheimer's disease and mild cognitive impairment: A randomized placebo-controlled trial. Brain Behav Immun. 2022;99:289. 10.1016/j.bbi.2021.10.014
